We're on a mission to deliver products and services to healthcare providers affordably, reliably, and with an unwavering focus on customer service and stakeholder needs.
learn more
For more information on our range of emergency contraceptive products:
click here
Afaxys Pharma provides reliable, affordable access to healthcare products for the public healthcare sector.
Afaxys Pharma brings a strong portfolio of branded and generic oral contraceptives to the public health market. We are dedicated to offering a sustainable supply of quality, affordable women's healthcare products and services for the public health sector.
Read More
Our core product line offers reliable, consistent, and affordable access to quality women's healthcare options to public health professionals and their patients.
Read More
Afaxys Group Services connects its members to suppliers who provide mission-critical products and services.
Afaxys Group Services negotiates favorable pricing across a broad base of healthcare products and services so its members have access to best-in-class suppliers and service providers. Our strategic sourcing business model enables Afaxys to secure and provide consistent and reliable access to quality products and services at an affordable price.
Read MoreAfaxys Pharma offers a wide spectrum of oral and emergency contraceptives.
To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA MedWatch Program at www.fda.gov/medwatch or 1-800-FDA-1088.
ella® is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive.
The most common side effects of ella (ulipristal acetate) tablets include headache (18%), abdominal pain (12%), nausea (12%), dysmenorrhea (9%), fatigue (6%), and dizziness (5%). ella is contraindicated in women with a known or suspected pregnancy, and should not replace a regular method of contraception. ella is not indicated for termination of an existing pregnancy. Women who become pregnant or complain of lower abdominal pain after taking ella should be evaluated for ectopic pregnancy. ella may alter the next expected menses. If menses is delayed beyond 1 week, pregnancy should be ruled out. A rapid return of fertility is likely following treatment with ella, therefore, a reliable barrier method of contraception should be used with subsequent acts of intercourse in that same menstrual cycle. Because ella and the progestin component of hormonal contraceptives both bind to the progesterone receptor, using them together could reduce their contraceptive effectiveness. After using ella, if a woman wishes to use hormonal contraception, she should do so no sooner than 5 days after intake of ella. Repeated use of ella within the same menstrual cycle is not recommended. Drugs or herbal products that induce CYP3A4 decrease the effectiveness of ella. ella does not protect against STI/HIV.
Reference:
ella® [prescribing information]. Charleston, SC: Afaxys Pharma, LLC; May 2018.
Please see full Prescribing Information here.
To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA MedWatch Program at www.fda.gov/medwatch or 1-800-FDA-1088.
Combination oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Combination oral contraceptives should not be used in women with any of the following conditions:
The use of oral contraceptives is associated with increased risks of several serious conditions including venous and arterial thrombotic and thromboembolic events (such as myocardial infarction, thromboembolism, and stroke), hepatic neoplasia, gallbladder disease, and hypertension, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as certain inherited or acquired thrombophilias, hypertension, hyperlipidemias, obesity, diabetes, and surgery or trauma with increased risk of thrombosis.
Practitioners prescribing oral contraceptives should be familiar with information relating to these risks.
The most serious reactions are discussed in detail in the full product labeling and include serious cardiovascular events and smoking, vascular events, and liver disease. Commonly reported adverse reactions include irregular uterine bleeding, nausea, breast tenderness, and headache.
Patients should be counseled that oral contraceptives do not protect against transmission of HIV (AIDS) and other sexually transmitted diseases (STDs) such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis.
Reference:
Aubra EQ™ [prescribing information]. Charleston, SC: Afaxys Pharma, LLC; April 2018.
Please see full Prescribing Information here.
To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA MedWatch Program at www.fda.gov/medwatch or 1-800-FDA-1088.
Combination oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Combination oral contraceptives should not be used in women with any of the following conditions:
The use of oral contraceptives is associated with increased risks of several serious conditions including venous and arterial thrombotic and thromboembolic events (such as myocardial infarction, thromboembolism, and stroke), hepatic neoplasia, gallbladder disease, and hypertension, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as certain inherited or acquired thrombophilias, hypertension, hyperlipidemias, obesity, diabetes, and surgery or trauma with increased risk of thrombosis.
Practitioners prescribing oral contraceptives should be familiar with information relating to these risks.
The most serious reactions are discussed in detail in the full product labeling and include serious cardiovascular events and smoking, vascular events, and liver disease. Commonly reported adverse reactions include irregular uterine bleeding, nausea, breast tenderness, and headache.
Patients should be counseled that oral contraceptives do not protect against transmission of HIV (AIDS) and other sexually transmitted diseases (STDs) such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis.
Reference:
Chateal EQ™ [prescribing information], Charleston, SC: Afaxys Pharma, LLC; May 2018.
Please see full Prescribing Information here.
To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA MedWatch Program at www.fda.gov/medwatch or 1-800-FDA-1088.
Cyred EQ™ is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, combination oral contraceptives, including Cyred EQ™, should not be used by women over 35 years of age who smoke.
Do not prescribe combined oral contraceptives (COCs) to women who currently have the following conditions:
The most serious reactions are discussed elsewhere in the labeling and include serious cardiovascular events and smoking, vascular events, and liver disease. Commonly reported adverse reactions include irregular uterine bleeding, nausea, breast tenderness, and headache.
Patients should be counseled that Cyred EQ™ does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
Reference:
Cyred EQ™ [prescribing information]. Charleston, SC: Afaxys Pharma, LLC; May 2018.
Please see full Prescribing Information here.
To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA MedWatch Program at www.fda.gov/medwatch or 1-800-FDA-1088.
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA MedWatch Program at www.fda.gov/medwatch or 1-800-FDA-1088.
Tarina Fe 1/20 EQ™ is a combined oral contraceptive (COC) indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Do not prescribe Tarina Fe 1/20 EQ™ to women who currently have the following conditions:
The most serious reactions are discussed above and include serious cardiovascular events and smoking, vascular events, and liver disease. Commonly reported adverse reactions include irregular uterine bleeding, nausea, breast tenderness, and headache.
Patients should be counseled that Tarina Fe 1/20 EQ™ does not protect against HIV
infection (AIDS) and other sexually transmitted diseases.
Reference:
Tarina Fe 1/20 EQ™ [prescribing information]. Charleston, SC: Afaxys Pharma, LLC; May 2018.
Please see full Prescribing Information here.
To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA MedWatch Program at www.fda.gov/medwatch or 1-800-FDA-1088.
VyLibra is a combined oral contraceptive (COC) indicated for use by women to prevent pregnancy.
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Do not prescribe VyLibra to women who are known to have the following conditions:
The most serious reactions are discussed elsewhere in the labeling and include serious cardiovascular events and smoking, vascular events and liver disease. Commonly reported adverse reactions include irregular uterine bleeding, nausea, breast tenderness and headache.
Patients should be counseled that VyLibra does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
Reference:
VyLibra® [prescribing information]. Charleston, SC: Afaxys Pharma, LLC; November 2017.
Please see full Prescribing Information here.
To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA MedWatch Program at www.fda.gov/medwatch or 1-800-FDA-1088.
Tri-VyLibra is an estrogen/progestin combined oral contraceptive (COC) indicated for use by women to prevent pregnancy. Tri-VyLibra is also indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Tri-VyLibra should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control.
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Do not prescribe Tri-VyLibra to women who are known to have the following conditions:
The most serious reactions are discussed elsewhere in the labeling and include serious cardiovascular events and smoking, vascular events and liver disease. Commonly reported adverse reactions include irregular uterine bleeding, nausea, breast tenderness and headache.
Patients should be counseled that Tri-VyLibra does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
Reference:
Tri-VyLibra® [prescribing information]. Charleston, SC: Afaxys Pharma, LLC; November 2017.
Please see full Prescribing Information here.
To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA MedWatch Program at www.fda.gov/medwatch or 1-800-FDA-1088.
Click on product image for safety information and warnings, including Black Box warning.
Afaxys Pharma is focused on product safety by working with our manufacturing suppliers and assuring ongoing safety monitoring and evaluation of its products. Our suppliers have FDA-approved manufacturing plants.
We are committed to the safe and effective use of our products.
